•  
  •  
  •  
  •  

2025-10-24 01:46:56

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Sagar Cements Ltd reports consolidated loss of Rs. 42.31 crores in Q2FY26
  • PTC India Financial Services Ltd consolidated Q2FY26 net profit at Rs. 88.14 crores
  • The South India Paper Mills Ltd Q2FY26 PAT at Rs. 2.81 crore
  • CCAvenue Further Strengthens its Partnership with Ujjivan Small Finance Bank with White-Labelled Payment Gateway Solutions
  • SBI General Insurance Outpaces Industry with 10.7% Growth in H1FY26

Keywords Selected:  INE987B01026

Research

  • Natco Pharma - Natco and Teva launch Revlimid in the US - ICICI Securities

Stock Report

  • NATCO Pharma Limited - Legal update regarding Risdiplam
  • Legal update regarding Risdiplam - Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal
  • NATCO Pharma Ltd updates on acquisition of Adcock Ingram
  • NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • NATCO Pharma Ltd - Legal Update regarding Risdiplam
  • Mylan and Novo Nordisk reach settlement of US patent ligitation related to Ozempic
  • NATCO Pharma Canada Inc. announces US$ 8 million investment in eGenesis, Inc.
  • Natco Pharma Ltd announces submission of Abbreviated New Drug Application
  • NATCO Pharma Ltd updates on complaint by Fresenius
  • NATCO Pharma Ltd receives warning letter from USFDA for facility in Kothur, Telangana
  • NATCO Pharma Limited invests around US$ 2 million in Cellogen Therapeutics Private Limited
  • Natco Pharma Ltd and Breckenridge dismissed from antitrust lawsuit
  • Operations disrupted at NATCO Pharma's Manali, Chennai factory
  • NATCO Pharma announces successful completion of USFDA inspection
  • Natco Pharma Ltd receives 8 observations from USFDA for Pharma Division at Kothur
  • NATCO Pharma Ltd included as defendant in antitrust lawsuit in the US
  • NATCO files generic Erdafitinib Tablets in USA
  • NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market
  • Natco Pharma receives EIR from USFDA for Vizag facility
  • NATCO Pharma Limited to form subsidiary in Indonesia
  • NATCO launches additional strengths for the Generic Version of Revlimid® in USA
  • Natco Pharma Ltd board approves buyback

Latest Post

  • Sagar Cements Ltd reports consolidated loss of Rs. 42.31 crores in Q2FY26
  • PTC India Financial Services Ltd consolidated Q2FY26 net profit at Rs. 88.14 crores
  • The South India Paper Mills Ltd Q2FY26 PAT at Rs. 2.81 crore
  • CCAvenue Further Strengthens its Partnership with Ujjivan Small Finance Bank with White-Labelled Payment Gateway Solutions
  • SBI General Insurance Outpaces Industry with 10.7% Growth in H1FY26


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024